insights_auto
4142 میں کمی کیوں آئی؟ 6.62%?
گہرائی سے تحقیق کریںchevron_right
4142:TPE
Adimmune Corp
NT$14.80
arrow_downward
-6.62%(-1.05) 1 دن
20 نومبر, 1:30:09 PM GMT +8 · TWD
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_auto4142 کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
NT$15.75
اعلی
NT$15.75
کم
NT$14.80
مارکیٹ کی سرمایہ کاری
6.36 ارب
اوسط والیوم
11.26 لاکھ
والیوم
16.29 لاکھ
P/E تناسب
85.76
52 ہفتے میں اعلی
NT$21.50
52 ہفتے کا کم
NT$14.80
EPS
NT$0.17
بقایہ شیئرز
23.53 کروڑ
ملازمین کی تعداد
564
کھولیں
NT$15.75
اعلی
NT$15.75
کم
NT$14.80
مارکیٹ کی سرمایہ کاری
6.36 ارب
اوسط والیوم
11.26 لاکھ
والیوم
16.29 لاکھ
P/E تناسب
85.76
52 ہفتے میں اعلی
NT$21.50
52 ہفتے کا کم
NT$14.80
EPS
NT$0.17
بقایہ شیئرز
23.53 کروڑ
ملازمین کی تعداد
564
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
The Motley Fool
·
58 منٹ پہلے
Nvidia Has Lost More Than the Market Value of 495 S&P 500 Companies in 6 Weeks -- and Its Downtrend May Be Just Beginning
BeInCrypto
·
1 گھنٹہ پہلے
S&P 500 Logs Its Longest Losing Streak Since 2024. Here’s What Happened Last Time
Wisevoter
·
1 گھنٹہ پہلے
S&P 500 Slides Into Correction Territory
MarketForces Africa
·
1 گھنٹہ پہلے
S&P 500, Nasdaq, Dow Jones Dip Amidst Anthropic IPO Debut
پروفائل
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp کے بارے میں